Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

JAMA - Journal of the American Medical Association - United States
doi 10.1001/jama.297.6.591
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Medical Association (AMA)

Related search

Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

JAMA - Journal of the American Medical Association
Medicine
2000English

Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

ACC Current Journal Review
2002English

Glycoprotein IIb/IIIa Induced Coronary Thrombolysis

Heart
2002English

Cost-Effectiveness of Platelet Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Non-St-Elevation Acute Coronary Syndromes

Circulation
Cardiovascular MedicinePhysiologyCardiology
2000English

Off-Target Effects of Glycoprotein IIb/IIIa Receptor Inhibitors

Cardiology Journal
MedicineCardiovascular MedicineCardiology
2014English

Current Evidence for the Use of Platelet Gpiib/Iiia Receptor Inhibitors in Acute Coronary Syndromes

The Internet Journal of Anesthesiology
1999English

Infarct Angioplasty: Beyond Stents and Glycoprotein IIb/IIIa Inhibitors

Heart
Cardiovascular MedicineCardiology
2005English

Platelet Inhibition After Glycoprotein IIb/IIIa Inhibitor Therapy

Circulation
Cardiovascular MedicinePhysiologyCardiology
2001English

Deaths Associated With Platelet Glycoprotein IIb/IIIa Inhibitor Treatment

Heart
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy